Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

U.S. FDA accepts and grants Priority Review for the Biologics License Application for ifinatamab deruxtecan. The application ...

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place ...

The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that ...

Merck (MRK) closed at $120.15 in the latest trading session, marking a -1.05% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.02%. Elsewhere, the Dow saw an ...

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.

In the trailing-twelve-months (TTM) as of 3/24/26, 64% of the companies in the S&P 500 reported GAAP Earnings that are lower ...

Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...

Regulatory filings show that Terns ultimately accepted an offer 15% lower than a previous proposal as four companies vied for ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on ...